文献速递免疫规划

带状疱疹疫苗的真实世界安全性:基于疫苗不良事件报告系统(2006年5月至2024年12月)的药物警戒研究

Real-world safety of herpes zoster vaccines: A pharmacovigilance study based on the vaccine adverse event reporting system (may 2006-december 2024).
PubMed 文献 · Vaccine · 2025-08-19

该研究分析2006年5月至2024年12月疫苗不良事件报告系统的个体病例安全报告,比较重组带状疱疹疫苗(RZV)与减毒活带状疱疹疫苗(ZVL)的安全性。单苗报告中,严重不良事件在ZVL占11.2%、RZV占4.6%,死亡结局分别占0.5%和0.3%;RZV相关不良事件主要为短暂反应原性,ZVL与带状疱疹再激活及神经和眼科并发症关联更强。RZV的吉兰-巴雷综合征信号不一致(4种方法中2种检出),需进一步研究;未发现过敏反应或晕厥的信号不平衡。

要点

  • 单苗报告中严重不良事件ZVL占11.2%、RZV占4.6%,死亡结局分别占0.5%和0.3%。
  • RZV相关不良事件主要为短暂反应原性,ZVL与带状疱疹再激活及神经和眼科并发症关联更强。
  • RZV的吉兰-巴雷综合征信号不一致(4种方法中2种检出),需进一步研究。

核心结论

  • 这些发现提供了令人安心的真实世界证据,支持RZV的临床安全性。

研究设计与样本

  • 分析2006年5月至2024年12月疫苗不良事件报告系统的个体病例安全报告,按疫苗类型和不良事件严重性进行描述性分析和发病时间分析。
  • 在系统器官分类、高位语和首选语水平进行不一致性分析,首选语信号按指定医疗事件和重要医疗事件标准优先。
  • 使用标准MedDRA查询评估过敏反应、吉兰-巴雷综合征和晕厥三种特别关注不良事件(若有)。

主要发现

  • 单苗个体病例安全报告(占总报告>90%)中,严重不良事件在ZVL占11.2%、RZV占4.6%,死亡结局分别占0.5%和0.3%。
  • 两种疫苗的大多数报告来自美国,ZVL病例主要在2017年之前记录;报告病例以女性和60-69岁人群为主,发生严重不良事件的患者一般年龄更大。
  • 大多数不良事件发生在接种后≤7天(峰值0-2天),严重不良事件发生晚于非严重事件。
  • RZV相关不良事件主要表现为短暂反应原性,ZVL与带状疱疹再激活及神经和眼科并发症关联更强。
  • 两种疫苗均未显示过敏反应或晕厥的信号不平衡;RZV的吉兰-巴雷综合征信号不一致(4种方法中2种检出),需进一步研究以明确潜在安全性影响。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • RZV的吉兰-巴雷综合征信号不一致(4种方法中2种检出),需进一步研究以明确潜在安全性影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: While the adjuvanted recombinant zoster vaccine (RZV) is preferred for herpes zoster (HZ) prevention due to its superior efficacy, emerging evidence suggests a potentially elevated reactogenicity risk relative to the live attenuated zoster vaccine (ZVL). This research aims to further assess the safety profiles of both vaccines, particularly the risk of serious adverse events following immunization (AEFIs) to provide more evidence for clinical decision. METHODS: Individual case safety reports from the Vaccine Adverse Event Reporting System (May 2006-December 2024) were analyzed. Descriptive and time-to-onset (TTO) analyses were performed by vaccine type and AEFI seriousness. Disproportionality analyses were conducted at the System Organ Class, High-Level Term, and Preferred Term (PT) levels, with PT signals prioritized by the Designated Medical Event and Important Medical Event criteria. Additionally, three adverse events of special interest-anaphylactic reaction, Guillain-Barré syndrome (GBS) and syncope, were assessed using Standardized MedDRA Queries if available. RESULTS: For monotherapy ICSRs (>90 % of total), serious AEFIs occurred in 11.2 % of ZVL and 4.6 % of RZV recipients, with fatal outcomes documented in 0.5 % and 0.3 % of cases respectively. The majority of ICSRs for both vaccines originated from the US, with ZVL cases primarily recorded prior to 2017. For both vaccines, females and individuals aged 60-69 years predominated among reported cases; patients experiencing serious AEFIs were generally older. Most AEFIs occurred ≤7 days post-vaccination (peak: 0-2 days). Serious AEFIs occurred later than non-serious events. RZV-associated AEs primarily manifested as transient reactogenicity, whereas ZVL showed stronger associations with HZ reactivation along with neurological and ophthalmic complications. Neither vaccine exhibited disproportionality signals for anaphylaxis or syncope. However, GBS signals were inconsistent for RZV(detected by 2/4 methodologies), warranting further investigation to clarify potential safety implications. CONCLUSION: These findings provide reassuring real-world evidence supporting RZV's clinical safety.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Cai H, Jia B, Song Z, et al. Real-world safety of herpes zoster vaccines: A pharmacovigilance study based on the vaccine adverse event reporting system (may 2006-december 2024). Vaccine. 2025. PMID: 40834551. doi:10.1016/j.vaccine.2025.127628

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。